Comprehensive Characterization of Prognostic Long Noncoding RNAs in Osteosarcoma.
Journal
BioMed research international
ISSN: 2314-6141
Titre abrégé: Biomed Res Int
Pays: United States
ID NLM: 101600173
Informations de publication
Date de publication:
2020
2020
Historique:
received:
27
05
2020
revised:
17
07
2020
accepted:
22
07
2020
entrez:
10
9
2020
pubmed:
11
9
2020
medline:
28
4
2021
Statut:
epublish
Résumé
The molecular mechanism of osteosarcoma (OS) based on protein-coding genes has largely been studied in the past decades. However, much remains to be explored when it comes to the role that long noncoding RNAs (lncRNAs) play in the pathogenesis and progression of OS and how they are associated with OS metastasis. In the present study, we collected RNA-seq-based gene expression data of 82 OS samples from the Therapeutically Applicable Research To Generate Effective Treatments (TARGET) database, along with their clinical information. We found that 50 lncRNAs were significantly associated with patients' survival by univariable Cox regression model. Moreover, we built multivariable Cox regression model based on 7 lncRNAs and successfully stratified patients into two risk groups, which exhibited significantly different prognostic outcomes. Significantly enriched Gene Ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways detected by differential expression analysis on DEGs between the two groups with different prognostic outcomes were both immune-related, indicating that such GO terms and pathways are critical for OS survival. Among the seven lncRNA signatures,
Identifiants
pubmed: 32908905
doi: 10.1155/2020/6725753
pmc: PMC7468628
doi:
Substances chimiques
Hedgehog Proteins
0
RNA, Long Noncoding
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6725753Informations de copyright
Copyright © 2020 Hua Gao et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
JAAPA. 2018 Aug;31(8):15-19
pubmed: 29979330
Am J Transl Res. 2016 Dec 15;8(12):5330-5337
pubmed: 28078006
Cancer Immunol Res. 2014 Sep;2(9):823-30
pubmed: 25187272
Oncol Rep. 2016 Oct;36(4):2033-40
pubmed: 27513470
Cell Death Dis. 2016 Sep 29;7(9):e2389
pubmed: 27685633
Cancer Immunol Immunother. 2018 Nov;67(11):1659-1667
pubmed: 30232519
Nature. 2018 Mar 15;555(7696):371-376
pubmed: 29489755
J Cell Biochem. 2019 Jun;120(6):10228-10238
pubmed: 30582201
Am J Transl Res. 2016 Oct 15;8(10):4095-4105
pubmed: 27829995
BMC Bioinformatics. 2013 Jan 16;14:7
pubmed: 23323831
Onco Targets Ther. 2018 Oct 16;11:7005-7009
pubmed: 30410357
Nucleic Acids Res. 2019 Jan 8;47(D1):D330-D338
pubmed: 30395331
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
Mol Ther Nucleic Acids. 2020 Mar 6;19:1470-1481
pubmed: 32160715
Cancer Treat Rev. 2006 Oct;32(6):423-36
pubmed: 16860938
Orthop Clin North Am. 2016 Jan;47(1):283-92
pubmed: 26614941
Immunol Rev. 2017 Mar;276(1):80-96
pubmed: 28258692
Arch Pharm Res. 2015 Mar;38(3):346-57
pubmed: 25575627
Br J Haematol. 2012 Jan;156(2):213-24
pubmed: 22098460
Cell Death Dis. 2018 Jun 13;9(6):701
pubmed: 29899399
Nucleic Acids Res. 2011 Jan;39(Database issue):D800-6
pubmed: 21045057
Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):5924-8
pubmed: 17062662
Tumour Biol. 2016 Oct;37(10):13403-13412
pubmed: 27460090
IUBMB Life. 2017 Nov;69(11):867-876
pubmed: 28960757
BMC Musculoskelet Disord. 2016 Dec 28;17(1):503
pubmed: 28031047
J Craniovertebr Junction Spine. 2015 Jan-Mar;6(1):21-9
pubmed: 25788817
Nucleic Acids Res. 2000 Jan 1;28(1):27-30
pubmed: 10592173
Biochim Biophys Acta. 2014 Nov;1839(11):1097-109
pubmed: 25159663
Cell Immunol. 2019 Sep;343:103711
pubmed: 29117898
Mol Cancer. 2018 May 12;17(1):89
pubmed: 29753317